NEUROCRINE BIOSCIENCES INC (NBIX)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
📈 **POSITIVE** • Medium confidence analysis (73%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business